nach oben

Current Rheumatology Reports

Erschienen in:

01.12.2010

Orbital Inflammatory Pseudotumors: Etiology, Differential Diagnosis, and Management

verfasst von: Gabriela M. Espinoza

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

Orbital inflammation is typically an idiopathic process that occasionally may be identified with a specific local or systemic disease as the causative agent. Orbital inflammatory pseudotumor (also known as idiopathic orbital inflammation syndrome, orbital pseudotumor, nonspecific orbital inflammation, and orbital inflammatory syndrome) is defined as an idiopathic tumor-like inflammation consisting of a pleomorphic cellular response and a fibrovascular tissue reaction. Various rheumatologic disorders are associated with orbital inflammation and must be ruled out in cases of orbital inflammatory pseudotumor, including Wegener’s granulomatosis, giant cell arteritis, systemic lupus erythematosus, dermatomyositis, and rheumatoid arthritis. The mainstay of therapy is corticosteroid therapy, although there is an increasing trend toward use of antimetabolites, alkylating agents, cytotoxic agents, and other immunosuppressive agents.

Jacobs D, Galetta S: Diagnosis and management of orbital pseudotumor. Ophthalmology 2002, 13:347–351.

Mombaerts I, Goldschmeding R, Schlingemann RO, Koornneef L: What is orbital pseudotumor? Surv Ophthalmol 1996, 41:66–78.CrossRefPubMed

Yuen SJA, Rubin PAD: Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002, 15:121–126.CrossRefPubMed

Alshaikh M, Kakakios AM, Kemp AS: Orbital myositis following streptococcal pharyngitis. J Paediatr Child Health 2008, 44:233–234.CrossRefPubMed

Mackie SL, Keat A: Poststreptococcal reactive arthritis: what is it and how do we know? Rheumatology 2004, 43:949–954.CrossRefPubMed

Dale RC, Candler PM, Church AJ, et al.: Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006, 172:187–197.CrossRefPubMed

Venuta A, Ferrari P, Beverelli A, et al.: Acute post-streptococcal polymyalgia: two new cases with a review of the literature. Eur J Pediatr 1995, 154:475–476.CrossRefPubMed

Nieto JC, Kim N, Lucarelli MJ: Dacryoadenitis and orbital myositis associated with lyme disease. Arch Ophthalmol 2008, 126:1165–1166.CrossRefPubMed

Kawasaki A, Borruat FX: An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. Am J Ophthalmol 2003, 136:574–575.CrossRefPubMed

10.

Badilla J, Dolman P: Orbital myositis involving the oblique muscles associated with herpes zoster ophthalmicus. Ophthal Plast Reconstr Surg 2007, 23:411–413.CrossRefPubMed

11.

Volpe NJ, Shore JW: Orbital myositis associated with herpes zoster. Arch Ophthalmol 1991, 109:471–472.PubMed

12.

Sobrin L, Kim E, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895–900.CrossRefPubMed

13.

Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925–930.CrossRefPubMed

14.

Atabay C, Tyutyunikov A, Scalise D, et al.: Serum antibodies reactive with eye muscle membrane antigens are detected in patients with nonspecific orbital inflammation. Ophthalmology 1995, 102:145–153.PubMed

15.

Yuen SJA, Rubin PAD: Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol 2003, 121:491–499.CrossRefPubMed

16.

Lanciano R, Fowble B, Sergott RC, et al.: The results of radiotherapy for orbital pseudotumor. Int J Radiat Oncol Biol Phys 1990, 18:407–411.PubMed

17.

Sergott R, Glaser J, Charyulu K: Radiotherapy for idiopathic inflammatory orbital pseudotumor: indications and results. Arch Ophthalmol 1981, 99:8536.

18.

Orcutt J, Garner A, Henk J, Wright J: Treatment of idiopathic inflammatory orbital pseudotumors by radiotherapy. Br J Ophthalmol 1983, 67:570–574.CrossRefPubMed

19.

Smitt MC, Donaldson SS: Radiation therapy for benign disease of the orbit. Semin Radiat Oncol 1999, 9:179–189.CrossRefPubMed

20.

Zacharopoulos IP, Papadaki T, Manor RS, Briscoe D: Treatment of idiopathic orbital inflammatory disease with cyclosporine-A: a case presentation. Semin Ophthalmol 2009, 24:260–261.CrossRefPubMed

21.

Bielory L, Frohman LP: Low-dose cyclosporine therapy of granulomatous optic neuropathy and orbitopathy. Ophthalmology 1991, 98:1732–1736.PubMed

22.

• Buell C, Koo J: Long-term safety of mycophenolate mofetil and cyclosporine: a review. J Drugs Dermatol 2008, 7:741–748. This was a meta-analysis review of CsA use that examined its safety profile.PubMed

23.

Diaz-Llopis M, Menezo JL: Idiopathic inflammatory orbital pseudotumor and low-dose cyclosporine. Am J Ophthalmol 1989, 107:547–548.PubMed

24.

Falcini F, Simonini G, Resti M, Cimaz R: Recurrent orbital pain and diplopia in a 12 year old boy. Ann Rheum Dis 2002, 61:93–94.CrossRefPubMed

25.

Sanchez-Roman J, Varela-Aguilar JM, Bravo-Ferrer J, et al.: Idiopathic orbital myositis: treatment with cyclosporin. Ann Rheum Dis 1993, 52:84–85.CrossRefPubMed

26.

• Gumus K, Mirza GE, Cavanagh HD, Karakucuk S: Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature. Eye Contact Lens 2009, 35:275–278. This case report showed topical corticosteroid and CsA use to control orbital inflammation in a patient who did not achieve control and did not tolerate the side effects of oral corticosteroids and oral CsA.CrossRefPubMed

27.

Smith JR, Rosenbaum JT: A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001, 85:1220–1224.CrossRefPubMed

28.

Shah SS, Lowder CY, Schmitt MA, et al.: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992, 99:1419–1423.PubMed

29.

Osborne S, Sims JL, Rosser PM: Short-term use of infliximab in a case of recalcitrant idiopathic orbital inflammatory disease. Clin Experiment Ophthalmol 2009, 37:897–900.CrossRefPubMed

30.

• Sahlin S, Lignell B, Williams M, et al.: Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol 2009, 87:906–908. This case report showed successful treatment with infliximab of a very difficult subset of OIP patients.CrossRefPubMed

31.

Miquel T, Abad S, Badelon I, et al.: Successful treatment of idiopathic orbital inflammation with infliximab: an alternative to conventional steroid-sparing agents. Ophthal Plast Reconstr Surg 2008, 24:415–417.CrossRefPubMed

32.

Prendiville C, O’Doherty M, Moriarty P, Cassidy L: The use of infliximab in ocular inflammation. Br J Ophthalmol 2008, 92:823–825.CrossRefPubMed

33.

Wilson MW, Shergy WJ, Haik BG: Infliximab in the treatment of recalcitrant idiopathic orbital inflammation. Ophthal Plast Reconstr Surg 2004, 20:381–383.CrossRefPubMed

Titel: Orbital Inflammatory Pseudotumors: Etiology, Differential Diagnosis, and Management
verfasst von: Gabriela M. Espinoza
Publikationsdatum: 01.12.2010
Verlag: Current Science Inc.
Erschienen in: Current Rheumatology Reports / Ausgabe 6/2010
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-010-0128-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Is It All Central Sensitization? Role of Peripheral Tissue Nociception in Chronic Musculoskeletal Pain

Giant Cell Arteritis: Epidemiology, Diagnosis, and Management

Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?

Pulmonary Vasculitis: Clinical Presentation, Differential Diagnosis, and Management

The Role of Quantitative Sensory Testing in the Evaluation of Musculoskeletal Pain Conditions